These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12167381

  • 1. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.
    Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE.
    Eur J Heart Fail; 2002 Aug; 4(4):439-4. PubMed ID: 12167381
    [Abstract] [Full Text] [Related]

  • 2. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
    Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG.
    Circulation; 1998 May 05; 97(17):1708-15. PubMed ID: 9591765
    [Abstract] [Full Text] [Related]

  • 3. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.
    Fassbach M, Schwartzkopff B.
    Z Kardiol; 2005 May 05; 94(5):328-35. PubMed ID: 15868361
    [Abstract] [Full Text] [Related]

  • 4. Fibrosis of extracellular matrix is related to the duration of the disease but is unrelated to the dynamics of collagen metabolism in dilated cardiomyopathy.
    Rubiś P, Wiśniowska-Śmialek S, Wypasek E, Biernacka-Fijalkowska B, Rudnicka-Sosin L, Dziewiecka E, Faltyn P, Khachatryan L, Karabinowska A, Kozanecki A, Tomkiewicz-Pająk L, Podolec P.
    Inflamm Res; 2016 Dec 05; 65(12):941-949. PubMed ID: 27516211
    [Abstract] [Full Text] [Related]

  • 5. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients.
    Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Küry P, Strauer BE, Schwartzkopff B.
    Clin Res Cardiol; 2006 May 05; 95(5):261-9. PubMed ID: 16598395
    [Abstract] [Full Text] [Related]

  • 6. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology.
    Li MJ, Huang CX, Okello E, Yanhong T, Mohamed S.
    Can J Cardiol; 2009 Sep 05; 25(9):523-6. PubMed ID: 19746242
    [Abstract] [Full Text] [Related]

  • 7. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
    Wei Y, Cui C, Lainscak M, Zhang X, Li J, Huang J, Zhang H, Zheng Z, Hu S.
    J Cell Mol Med; 2011 Apr 05; 15(4):773-82. PubMed ID: 20219015
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Myocardial collagen turnover in hypertrophic cardiomyopathy.
    Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Miranda M, D'Alessandro G, Cacace A, Ciampi Q, Chiariello M.
    Circulation; 2003 Sep 23; 108(12):1455-60. PubMed ID: 12952838
    [Abstract] [Full Text] [Related]

  • 13. Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation.
    Reddy HK, Tjahja IE, Campbell SE, Janicki JS, Hayden MR, Tyagi SC.
    Mol Cell Biochem; 2004 Sep 23; 264(1-2):183-91. PubMed ID: 15544047
    [Abstract] [Full Text] [Related]

  • 14. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension.
    Lindsay MM, Maxwell P, Dunn FG.
    Hypertension; 2002 Aug 23; 40(2):136-41. PubMed ID: 12154103
    [Abstract] [Full Text] [Related]

  • 15. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
    Spinale FG, Coker ML, Bond BR, Zellner JL.
    Cardiovasc Res; 2000 May 23; 46(2):225-38. PubMed ID: 10773226
    [Abstract] [Full Text] [Related]

  • 16. Left ventricular reverse remodeling is not related to biopsy-detected extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy, regardless of the definition used for LVRR.
    Rubiś P, Wiśniowska-Śmiałek S, Biernacka-Fijałkowska B, Rudnicka-Sosin L, Wypasek E, Kozanecki A, Dziewięcka E, Faltyn P, Karabinowska A, Khachatryan L, Hlawaty M, Leśniak-Sobelga A, Kostkiewicz M, Płazak W, Podolec P.
    Heart Vessels; 2017 Jun 23; 32(6):714-725. PubMed ID: 28004175
    [Abstract] [Full Text] [Related]

  • 17. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S, Höyhtyä M, Mäkitaro R, Pääakkö P, Risteli J, Kinnula VL, Turpeenniemi-Hujanen T, Jukkola A.
    Clin Cancer Res; 2001 Jun 23; 7(6):1633-7. PubMed ID: 11410500
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.